Shilpen Patel, MD Fa CRO Fastro
About Shilpen Patel, MD Fa CRO Fastro
Shilpen Patel, MD, serves as the Executive Medical Director at Mirati Therapeutics, which was acquired by Bristol Myers Squibb. He has extensive experience in clinical research and healthcare, having held leadership roles at Roche, Gilead Sciences, and GRAIL, Inc., and is currently an Associate Professor at the University of Washington.
Current Role at Mirati Therapeutics
Shilpen Patel serves as the Executive Medical Director at Mirati Therapeutics, a position he has held since 2023. The company was acquired by Bristol Myers Squibb, enhancing its capabilities in developing innovative therapies. In this role, Patel is known for leading the global clinical efforts for the Phase 1 study of MRTX1133, which targets KRAS G12D mutated solid tumors. His leadership focuses on advancing clinical research and improving treatment options for patients.
Previous Experience at Roche
Before joining Mirati Therapeutics, Patel worked at Roche for three years in various capacities. He served as Principal Medical Director from 2021 to 2022 in South San Francisco, California. Prior to that, he held the position of Lead Medical Director from 2019 to 2021 in the San Francisco Bay Area. His time at Roche involved significant contributions to medical affairs and strategic clinical development.
Academic Role at University of Washington
Patel has been associated with the University of Washington since 2006, where he holds the position of Associate Professor in Global Health and Radiation Oncology. His long tenure at the university reflects his commitment to education and research in the field of oncology. He is involved in training future healthcare professionals and contributing to advancements in global health initiatives.
Education and Medical Training
Shilpen Patel's educational background includes a Bachelor of Science degree from Houston Christian University, where he studied Biology, Political Science, and Chemistry. He earned his MD from The University of Texas Medical Branch. Additionally, he completed a Radiation Oncology Residency Program at the University of Maryland School of Medicine, where he gained specialized training in radiation oncology.
Focus on Healthcare Quality and Diversity
Patel is actively involved in initiatives aimed at improving healthcare quality and access while ensuring fiscal responsibility. He emphasizes the importance of diversity, equity, and inclusion (DEI) within clinical research and healthcare settings. His approach includes engaging multidisciplinary teams to enhance patient outcomes and foster a more inclusive healthcare environment.